Capricor Therapeutics

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Capricor Therapeutics reports strong Q4 performance and advances DMD therapy

Capricor Therapeutics showcased strong financial performance, progress in DMD therapy, and strategic partnerships with Nippon Shinyaku and NS Pharma.
The company faces challenges in FDA interactions, share sales, and potential acquisition decisions, but opportunities lie in market expansion and community engagement.
Overall, Capricor's confidence in its therapies and partnerships positions it well for future growth and impact in the Duchenne Muscular Dystrophy space.
The call concluded with gratitude towards participants, supporters, and the Capricor team, highlighting a positive outlook for the company's future endeavors.

Capricor Therapeutics advances DMD programs and secures Japan distribution

Capricor Therapeutics made significant progress in Q1 2023 with advancements in DMD programs, manufacturing, and clinical trials.
While facing financial losses, the company's strategic strengths include FDA discussions, partnerships, and international expansion.
Challenges in financial stability and operational efficiency need to be addressed, but opportunities in funding, market expansion, and innovation are promising.

Capricor Therapeutics reports Q2 progress with positive clinical outcomes

Capricor Therapeutics showcased solid financial performance amid ongoing R&D investments, with a focus on advancing innovative therapies for Duchenne muscular dystrophy.
The company's strengths lie in positive clinical trial outcomes, regulatory support, and strategic board additions, positioning Capricor for future growth and success.
Challenges include financial sustainability, trial coordination, and manufacturing scalability, which require careful management to navigate effectively.
Opportunities in new indications, partnerships, upcoming milestones, and technology advancement offer avenues for expansion, value creation, and competitive differentiation.

Capricor Therapeutics achieves enrollment goal, eyes FDA approval acceleration

Capricor Therapeutics is making significant strides in its clinical trials and manufacturing capabilities, supported by a strong financial position. While challenges exist in managing expenses and navigating regulatory processes, the company is well-positioned to capitalize on growth opportunities in the biopharmaceutical sector.

Capricor Therapeutics reports positive trial results and strategic partnerships for growth

Capricor Therapeutics' Q4 2023 performance reflects a strong financial position but with a net loss, driven by positive trial results for CAP-1002 in DMD.
The company's strengths include successful trial outcomes, strategic partnerships, and advancements in exosome technology development.
Challenges include operational losses, regulatory hurdles, and market competition, while opportunities exist in partnerships, FDA interactions, and technology development.
Overall, Capricor Therapeutics is poised for growth with a focus on commercialization, regulatory progress, and expanding therapeutic applications.

Capricor Therapeutics excels in Q1 2024, poised for market expansion

Capricor Therapeutics shows strong financial performance and progress in DMD trial, positioning CAP-1002 favorably in the market.
Strategic focus on regulatory alignment, commercial readiness, and potential expansions highlight growth opportunities.
Challenges in regulatory compliance, operational execution, and market competition require proactive management strategies.
Overall, Capricor's advancements in therapy development and market positioning indicate a promising outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)

SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will host a webinar with the nonprofit organization Parent Project Muscular Dystrophy (PPMD) to review key regulatory details and provide clinical updates that support the advancement of its ongoing HOPE-3, Phase 3 clinical trial of CAP-1002 for treating Duchenne muscular dystrophy (DMD). The webinar will be held on Wednesday, October 25, 2023 at 1:00 p.m.

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002's Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $4.66. The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Capricor Therapeutics Announces $23 Million Registered Direct Offering

-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002's Path Towards a Biologics License Application (BLA)-

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry.

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

There is an ongoing phase 3 study, known as HOPE-3, deploying the use of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy; Interim analysis expected Q4 of 2023. A Type-B FDA meeting was held between the company and the FDA; Minutes from this FDA meeting are going to be released when available. The global Duchenne Muscular Dystrophy Drugs market size is expected to reach $10.92 billion by 2028.

Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.

Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; On Track to Complete Enrollment and Report Interim Analysis in Fourth Quarter of 2023- -Held Type-B Clinical Meeting with the FDA to Discuss CAP-1002's Pathway Towards Potential Biologics License Application Submission- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Calif.

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023. Management will then host a webcast and conference call at 4:30 p.m.

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company.

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D.

-John Hopkins School of Medicine Clinical Director Joins Capricor's Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience-

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function-

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002's Pathway Towards Potential Biologics License Application Submission Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002's Pathway Towards Potential Biologics License Application Submission

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen, this is the conference operator. Welcome to Capricor First Quarter 2023 Financial Results and Corporate Update Call.

Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023-

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m.

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

-Capricor's StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics- -Capricor's StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call.

Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call Transcript

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023-

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET- -Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

-HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement- -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-

Capricor Therapeutics Receives Clinical Research Forum's 2023 Top Ten Clinical Research Achievement Award

-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise-

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

News for Capricor Therapeutics Stock (CAPR)